Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB9LE1)

• Drug Name: Geranyl Diphosphate Drug Info
• Synonyms: Geranyl diphosphate; geranyl pyrophosphate; 763-10-0; Neryl pyrophosphate; Polyprenyl diphosphate; CHEBI:17211; Polyisopentenyldiphosphate; Polyisopentenylpyrophosphate; trans-Geranyl pyrophosphate; trans-Polyisopentenyldiphosphate; geranyl-PP; all-trans-Polyprenyl diphosphate; GPP; GVVPGTZRZFNKDS-JXMROGBWSA-N; geranyl-diphosphate; (2E)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate; geranyl-pyrophosphate; trans-3,7-Dimethyl-2,6-octadienyl pyrophosphate; [(2E)-3,7-dimethylocta-2,6-dienyl] phosphono hydrogen phosphate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 445995
  ChEBI ID: CHEBI:17211
  CAS Number: CAS 763-10-0
  TTD Drug ID: DMB9LE1

Molecule-Related Drug Atlas

Drug(s) Targeting Geranyltranstransferase (FDPS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[5]
Minodronate	DM50PMY	Osteoporosis	FB83.0	Approved	[6]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[5]
Alendronate	DMY2KX9	Bone Paget disease		Approved	[5]
Pamidronate	DMB4AVP	Bone Paget disease		Approved	[7]
Incadronate	DM3DSVJ	Hypercalcaemia	5B91.0	Approved	[8]
Risedronate	DM5FLTY	Bone Paget disease		Approved	[9]
NERIDRONIC ACID	DMMPG5V	Bone disease	FC0Z	Approved	[10]
Zarnestra	DMF30HL	Acute myeloid leukaemia	2A60	Phase 3	[11]
GERANYLGERANYL DIPHOSPHATE	DMJZ0AM	Discovery agent	N.A.	Investigative	[12]

Drug(s) Affected By Mevalonate kinase (MVK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[13]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[14]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[15]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[16]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[19]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[21]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[22]

Drug(s) Affected By 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[23]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[24]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[25]
Digoxin	DMQCTIH	Arrhythmia	BC9Z	Approved	[26]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[27]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[28]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[29]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[15]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[16]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Geranyltranstransferase (FDPS)	TTIKWV4	FPPS_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Regulation of Drug Effects	[3]
Mevalonate kinase (MVK)	OTHJCUKT	KIME_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3051).
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] Quantitative determination of geranyl diphosphate levels in cultured human cells. Lipids. 2009 Nov;44(11):1055-62. doi: 10.1007/s11745-009-3355-x. Epub 2009 Oct 24.
• [4] Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways. J Lipid Res. 1997 Nov;38(11):2216-23.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64.
• [7] Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24.
• [8] Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.
• [9] Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14.
• [10] Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [13] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [14] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [15] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [16] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [17] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [18] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [19] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [20] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [21] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [22] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [23] Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-Delta24-reductase-deficient cell line. Biochem J. 2009 May 13;420(2):305-15.
• [24] Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
• [25] Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
• [26] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [27] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [28] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [29] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [30] PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. FEBS Lett. 2002 Jun 5;520(1-3):177-81.